
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx is a clinical-stage biopharmaceutical company that is making significant progress in its clinical drug development and RenovoCath commercialization, indicating strong potential for revenue growth. The recent positive 2nd interim analysis of its Phase III TIGeR-PaC trial and the increasing number of active commercial cancer centers also add to the company's positive outlook. The large market potential for its lead therapy candidate RenovoGem and key milestones expected to be reached in June 2026 and 2027 further solidify the company's promising future. With a strong balance sheet and a new CFO in place, RenovoRx is on track for success and presents high rewards for the risks involved.
Bears say
RenovoRx is a clinical-stage biopharmaceutical company with a promising patented Trans-Arterial Micro-Perfusion therapy platform. However, its current valuation may be overstated due to significant risks including balance sheet/liquidity risks and failure to gain regulatory approvals. The recent appointment of a new CFO and plans to expand to 36 active commercial cancer centers may contribute to potential revenue growth but may not be enough to offset these risks and lead to significant upside for investors. Additionally, the company's focus on local drug delivery carries high risks but may lead to improved therapeutic outcomes for cancer patients.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares